JP2021500390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500390A5 JP2021500390A5 JP2020523445A JP2020523445A JP2021500390A5 JP 2021500390 A5 JP2021500390 A5 JP 2021500390A5 JP 2020523445 A JP2020523445 A JP 2020523445A JP 2020523445 A JP2020523445 A JP 2020523445A JP 2021500390 A5 JP2021500390 A5 JP 2021500390A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- methoxy
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 150000003839 salts Chemical class 0.000 claims 33
- -1 6-Amino-4-methoxy-pyridazine-3-yl Chemical group 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 3
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- JUALOUHZJJERQT-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)F Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)F JUALOUHZJJERQT-UHFFFAOYSA-N 0.000 claims 2
- FGQMYZPXIOUMGB-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC(C)C Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC(C)C FGQMYZPXIOUMGB-UHFFFAOYSA-N 0.000 claims 2
- JKGMPLDOMCXRIO-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC(F)(F)F Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC(F)(F)F JKGMPLDOMCXRIO-UHFFFAOYSA-N 0.000 claims 2
- DBBVIMLMQLZJFR-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC(F)F Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC(F)F DBBVIMLMQLZJFR-UHFFFAOYSA-N 0.000 claims 2
- PYYOCJNMFRDSEU-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=CC=C1 Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=CC=C1 PYYOCJNMFRDSEU-UHFFFAOYSA-N 0.000 claims 2
- KPBROUBVBSSABA-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OCC)OC1=CC=CC=C1 Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OCC)OC1=CC=CC=C1 KPBROUBVBSSABA-UHFFFAOYSA-N 0.000 claims 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- FYEHZCHYPSYCHO-UHFFFAOYSA-N C1(N)=NN=C(C(=C1)C)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(F)C=C1 Chemical compound C1(N)=NN=C(C(=C1)C)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(F)C=C1 FYEHZCHYPSYCHO-UHFFFAOYSA-N 0.000 claims 1
- XAOSVOZSYZXLDC-UHFFFAOYSA-N CCOC1=CC(N)=NN=C1C1CCN(CC1)C(=O)C1=NC=C(OC2=CC=C(C=C2)C(F)(F)F)C(OC)=C1 Chemical compound CCOC1=CC(N)=NN=C1C1CCN(CC1)C(=O)C1=NC=C(OC2=CC=C(C=C2)C(F)(F)F)C(OC)=C1 XAOSVOZSYZXLDC-UHFFFAOYSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102100032273 DNA-directed RNA polymerase III subunit RPC6 Human genes 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 206010070538 Gestational hypertension Diseases 0.000 claims 1
- 201000005624 HELLP Syndrome Diseases 0.000 claims 1
- 101001088194 Homo sapiens DNA-directed RNA polymerase III subunit RPC6 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- KDZRRQSRUXMZAE-UHFFFAOYSA-N N1=C(C=C(C(=N1)C1CCN(CC1)C(=O)C1=CC(=C(OC2=CC=C(C=C2)C(F)(F)F)C=N1)OC)C)N Chemical compound N1=C(C=C(C(=N1)C1CCN(CC1)C(=O)C1=CC(=C(OC2=CC=C(C=C2)C(F)(F)F)C=N1)OC)C)N KDZRRQSRUXMZAE-UHFFFAOYSA-N 0.000 claims 1
- SMULRYIMTOWDEM-UHFFFAOYSA-N N1=NC(=CC(=C1C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=CC=C1)C)N Chemical compound N1=NC(=CC(=C1C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=CC=C1)C)N SMULRYIMTOWDEM-UHFFFAOYSA-N 0.000 claims 1
- DTAHYUKCFJTZCI-UHFFFAOYSA-N NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)F)OC Chemical compound NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)F)OC DTAHYUKCFJTZCI-UHFFFAOYSA-N 0.000 claims 1
- NGVFJNKJEASNHO-UHFFFAOYSA-N NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC)OC Chemical compound NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC)OC NGVFJNKJEASNHO-UHFFFAOYSA-N 0.000 claims 1
- WUUUUIADANIROZ-UHFFFAOYSA-N NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=CC=C1)OCC Chemical compound NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=CC=C1)OCC WUUUUIADANIROZ-UHFFFAOYSA-N 0.000 claims 1
- LIQDUYACZZTYON-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)C(F)(F)F Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)C(F)(F)F LIQDUYACZZTYON-UHFFFAOYSA-N 0.000 claims 1
- FFJOKVQUYMUXQG-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)Cl Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)Cl FFJOKVQUYMUXQG-UHFFFAOYSA-N 0.000 claims 1
- NXQHPTKYCXABEA-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC NXQHPTKYCXABEA-UHFFFAOYSA-N 0.000 claims 1
- ISKFEXMKGRHSNG-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC1CC1 Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC1CC1 ISKFEXMKGRHSNG-UHFFFAOYSA-N 0.000 claims 1
- MCGZNFLAJPTZIH-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OCC1=C(C=CC=C1)F Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OCC1=C(C=CC=C1)F MCGZNFLAJPTZIH-UHFFFAOYSA-N 0.000 claims 1
- TXHYVGLUNVAZDV-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OCC1=CC=C(C=C1)F Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OCC1=CC=C(C=C1)F TXHYVGLUNVAZDV-UHFFFAOYSA-N 0.000 claims 1
- BEOOJWVEKHNVBT-UHFFFAOYSA-N NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OCC)OC1=CC=C(C=C1)F Chemical compound NC1=CC=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OCC)OC1=CC=C(C=C1)F BEOOJWVEKHNVBT-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020170563A JP6979502B2 (ja) | 2017-10-27 | 2020-10-08 | ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577883P | 2017-10-27 | 2017-10-27 | |
| US62/577,883 | 2017-10-27 | ||
| US201862628313P | 2018-02-09 | 2018-02-09 | |
| US62/628,313 | 2018-02-09 | ||
| PCT/EP2018/079276 WO2019081637A1 (en) | 2017-10-27 | 2018-10-25 | CARBONYL PYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USES AS TRPC6 INHIBITORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170563A Division JP6979502B2 (ja) | 2017-10-27 | 2020-10-08 | ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021500390A JP2021500390A (ja) | 2021-01-07 |
| JP2021500390A5 true JP2021500390A5 (https=) | 2021-12-02 |
| JP7217273B2 JP7217273B2 (ja) | 2023-02-02 |
| JP7217273B6 JP7217273B6 (ja) | 2024-02-08 |
Family
ID=64270818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523445A Active JP7217273B6 (ja) | 2017-10-27 | 2018-10-25 | ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用 |
| JP2020170563A Active JP6979502B2 (ja) | 2017-10-27 | 2020-10-08 | ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170563A Active JP6979502B2 (ja) | 2017-10-27 | 2020-10-08 | ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US10889568B2 (https=) |
| EP (2) | EP3700902B8 (https=) |
| JP (2) | JP7217273B6 (https=) |
| KR (2) | KR20200125758A (https=) |
| CN (1) | CN111527078B (https=) |
| AU (2) | AU2018355743B2 (https=) |
| CA (1) | CA3078769A1 (https=) |
| CL (2) | CL2020001097A1 (https=) |
| CY (2) | CY1125488T1 (https=) |
| DK (2) | DK3700902T3 (https=) |
| ES (2) | ES2924933T3 (https=) |
| FI (1) | FI3700902T3 (https=) |
| HR (2) | HRP20220991T1 (https=) |
| HU (2) | HUE059450T2 (https=) |
| IL (2) | IL274039B (https=) |
| LT (2) | LT3700902T (https=) |
| MX (1) | MX387232B (https=) |
| MY (1) | MY202126A (https=) |
| PE (1) | PE20210154A1 (https=) |
| PH (1) | PH12020550503A1 (https=) |
| PL (2) | PL3700902T3 (https=) |
| PT (2) | PT3700902T (https=) |
| RS (2) | RS63535B1 (https=) |
| SA (1) | SA520411843B1 (https=) |
| SG (2) | SG10202011632RA (https=) |
| SI (2) | SI3786160T1 (https=) |
| TW (2) | TWI780246B (https=) |
| UA (1) | UA128474C2 (https=) |
| WO (1) | WO2019081637A1 (https=) |
| ZA (1) | ZA202002372B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202011632RA (en) * | 2017-10-27 | 2021-01-28 | Boehringer Ingelheim Int | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors |
| JP7291711B2 (ja) * | 2018-02-15 | 2023-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｒｐｃ６阻害剤 |
| CN111868055B (zh) * | 2018-02-16 | 2024-03-08 | 勃林格殷格翰国际有限公司 | Trpc6的抑制剂 |
| IL315313A (en) * | 2018-08-24 | 2024-10-01 | Xeniopro GmbH | Aromatic molecules for use in the treatment of pathological conditions |
| JP7585227B2 (ja) * | 2019-04-12 | 2024-11-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｒｐｃ６阻害剤 |
| JP7594274B2 (ja) | 2019-10-24 | 2024-12-04 | 国立大学法人大阪大学 | 難聴の予防および／または治療用医薬組成物 |
| WO2021160625A1 (en) | 2020-02-11 | 2021-08-19 | Klinikum Rechts Der Isar | Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices |
| AR121846A1 (es) | 2020-04-16 | 2022-07-13 | Teijin Pharma Ltd | Derivado de arilo o heteroarilo |
| JP7502462B2 (ja) * | 2020-04-16 | 2024-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器状態を処置するためのｔｒｐｃ６阻害剤 |
| CN113105318B (zh) * | 2021-02-23 | 2022-05-20 | 中山大学 | 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用 |
| AU2022366192A1 (en) | 2021-10-15 | 2024-02-29 | Boehringer Ingelheim International Gmbh | Trpc6 inhibitory compounds for treating sepsis |
| JP2025023360A (ja) * | 2021-12-06 | 2025-02-17 | 国立大学法人 熊本大学 | Ｔｒｐｃ６の発現を抑制する方法 |
| CN121729232A (zh) | 2023-08-18 | 2026-03-24 | 勃林格殷格翰国际有限公司 | 用于治疗局灶节段性肾小球硬化症的trpc6抑制剂 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0507863A4 (en) | 1989-12-28 | 1993-07-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| WO1993000313A2 (en) | 1991-06-27 | 1993-01-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| AU673569B2 (en) | 1992-12-02 | 1996-11-14 | Pfizer Inc. | Catechol diethers as selective PDE-IV inhibitors |
| ES2300151T3 (es) | 1998-09-22 | 2008-06-01 | Astellas Pharma Inc. | Derivados de cianofenilo. |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| JP2004525071A (ja) | 2000-07-20 | 2004-08-19 | ニューロジェン コーポレイション | カプサイシン受容体リガンド |
| JP4186518B2 (ja) * | 2001-06-15 | 2008-11-26 | アステラス製薬株式会社 | フェニルピリジン誘導体 |
| KR20040010713A (ko) | 2001-06-15 | 2004-01-31 | 야마노우치세이야쿠 가부시키가이샤 | 페닐피리딘 카보닐 피페라진 유도체 |
| NI200300045A (es) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
| DE10222291A1 (de) | 2002-05-18 | 2003-11-27 | Schlafhorst & Co W | Faserbandzuführeinrichtung |
| CN1150176C (zh) | 2002-05-22 | 2004-05-19 | 上海医药工业研究院 | 芳烷酮哌嗪衍生物及其应用 |
| AU2005296124A1 (en) | 2004-10-13 | 2006-04-27 | Neurogen Corporation | Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor |
| DE102005044814A1 (de) * | 2005-05-19 | 2006-11-23 | Grünenthal GmbH | Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| DOP2006000234A (es) | 2005-10-28 | 2007-05-31 | Lilly Co Eli | Inhibidores de cinasa |
| JP2009521448A (ja) | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
| JP5019768B2 (ja) | 2006-03-23 | 2012-09-05 | 独立行政法人科学技術振興機構 | 新規低分子化合物およびその製造方法 |
| PE20090188A1 (es) | 2007-03-15 | 2009-03-20 | Novartis Ag | Compuestos heterociclicos como moduladores de la senda de hedgehog |
| JP5082538B2 (ja) | 2007-03-28 | 2012-11-28 | Ｄｉｃ株式会社 | ピペラジン化合物 |
| JP2012512877A (ja) | 2008-12-18 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | セロトニン５−ｈｔ２ｂ受容体阻害剤 |
| US20100234603A1 (en) | 2009-03-13 | 2010-09-16 | Xin Linghu | Process for Making Substituted Aryl Sulfone Intermediates |
| US20110039850A1 (en) | 2009-08-12 | 2011-02-17 | Mhairi Copland | Leukemia Treatment |
| CN102686579A (zh) | 2009-10-09 | 2012-09-19 | Irm责任有限公司 | 作为gpr119活性调节剂的化合物和组合物 |
| CA2781210A1 (en) | 2009-11-18 | 2011-05-26 | Novartis Ag | Methods and compositions for treating solid tumors and other malignancies |
| MX2012010115A (es) | 2010-03-01 | 2013-02-26 | Gtx Inc | Compuestos para el tratamiento de cancer. |
| TWI525090B (zh) | 2010-04-27 | 2016-03-11 | Mitsubishi Tanabe Pharma Corp | Novel amide derivatives and their use as pharmaceuticals |
| MA34300B1 (fr) | 2010-05-13 | 2013-06-01 | Amgen Inc | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 |
| BR112013002112B1 (pt) | 2010-07-29 | 2021-04-06 | Rigel Pharmaceuticals, Inc. | Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição |
| WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| JP5800786B2 (ja) | 2011-10-26 | 2015-10-28 | 田辺三菱製薬株式会社 | 新規アミド誘導体を有効成分として含有する医薬組成物 |
| WO2013066714A1 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| CN103360343B (zh) | 2012-03-30 | 2017-04-19 | 凯惠药业(上海)有限公司 | 一种哌嗪酰胺类化合物的制备方法 |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| JP6581970B2 (ja) | 2013-05-27 | 2019-09-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物 |
| WO2015048547A2 (en) | 2013-09-26 | 2015-04-02 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| CA2934700A1 (en) | 2014-01-06 | 2015-07-09 | Rhizen Pharmaceuticals Sa | Glutaminase inhibitors |
| WO2015199206A1 (ja) * | 2014-06-27 | 2015-12-30 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する６員環誘導体 |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2017066705A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| CN107176927B (zh) | 2016-03-12 | 2020-02-18 | 福建金乐医药科技有限公司 | 组蛋白去甲基化酶lsd1抑制剂 |
| CN109152784B (zh) | 2016-03-16 | 2021-12-28 | 库拉肿瘤学公司 | 经取代的menin-mll抑制剂及使用方法 |
| JP2019526617A (ja) | 2016-06-20 | 2019-09-19 | ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー | 治療用化合物 |
| CN107540636A (zh) | 2016-06-29 | 2018-01-05 | 成都贝斯凯瑞生物科技有限公司 | 一种含氮杂环衍生物及其应用 |
| CN106317050B (zh) * | 2016-08-24 | 2018-11-23 | 烟台大学 | 一种苯基噻唑衍生物及其制备方法与应用 |
| WO2018159827A1 (ja) | 2017-03-03 | 2018-09-07 | 国立大学法人京都大学 | 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製 |
| WO2018170225A1 (en) | 2017-03-15 | 2018-09-20 | Athenex, Inc. | Biaryl piperidine amide compounds and methods of use thereof |
| SG10202011632RA (en) | 2017-10-27 | 2021-01-28 | Boehringer Ingelheim Int | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors |
| MA50906A (fr) * | 2017-11-16 | 2020-09-23 | Principia Biopharma Inc | Inhibiteurs d'immunoprotéasome |
| JP7291711B2 (ja) * | 2018-02-15 | 2023-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｒｐｃ６阻害剤 |
| CN111868055B (zh) * | 2018-02-16 | 2024-03-08 | 勃林格殷格翰国际有限公司 | Trpc6的抑制剂 |
-
2018
- 2018-10-25 SG SG10202011632RA patent/SG10202011632RA/en unknown
- 2018-10-25 UA UAA202003145A patent/UA128474C2/uk unknown
- 2018-10-25 KR KR1020207031025A patent/KR20200125758A/ko not_active Withdrawn
- 2018-10-25 PL PL18800513.6T patent/PL3700902T3/pl unknown
- 2018-10-25 LT LTEPPCT/EP2018/079276T patent/LT3700902T/lt unknown
- 2018-10-25 PT PT188005136T patent/PT3700902T/pt unknown
- 2018-10-25 PT PT201971942T patent/PT3786160T/pt unknown
- 2018-10-25 ES ES20197194T patent/ES2924933T3/es active Active
- 2018-10-25 RS RS20220752A patent/RS63535B1/sr unknown
- 2018-10-25 TW TW107137733A patent/TWI780246B/zh active
- 2018-10-25 PE PE2020000424A patent/PE20210154A1/es unknown
- 2018-10-25 RS RS20230382A patent/RS64271B1/sr unknown
- 2018-10-25 FI FIEP18800513.6T patent/FI3700902T3/fi active
- 2018-10-25 EP EP18800513.6A patent/EP3700902B8/en active Active
- 2018-10-25 DK DK18800513.6T patent/DK3700902T3/da active
- 2018-10-25 AU AU2018355743A patent/AU2018355743B2/en active Active
- 2018-10-25 MX MX2020004283A patent/MX387232B/es unknown
- 2018-10-25 TW TW109138850A patent/TWI780511B/zh active
- 2018-10-25 US US16/170,178 patent/US10889568B2/en active Active
- 2018-10-25 DK DK20197194.2T patent/DK3786160T3/da active
- 2018-10-25 WO PCT/EP2018/079276 patent/WO2019081637A1/en not_active Ceased
- 2018-10-25 EP EP20197194.2A patent/EP3786160B1/en active Active
- 2018-10-25 HR HRP20220991TT patent/HRP20220991T1/hr unknown
- 2018-10-25 CA CA3078769A patent/CA3078769A1/en active Pending
- 2018-10-25 US US16/170,154 patent/US10800757B2/en not_active Ceased
- 2018-10-25 HU HUE20197194A patent/HUE059450T2/hu unknown
- 2018-10-25 HR HRP20230502TT patent/HRP20230502T1/hr unknown
- 2018-10-25 PL PL20197194.2T patent/PL3786160T3/pl unknown
- 2018-10-25 CN CN201880070122.4A patent/CN111527078B/zh active Active
- 2018-10-25 SG SG11202003367TA patent/SG11202003367TA/en unknown
- 2018-10-25 KR KR1020207014013A patent/KR102724066B1/ko active Active
- 2018-10-25 ES ES18800513T patent/ES2946274T3/es active Active
- 2018-10-25 SI SI201830732T patent/SI3786160T1/sl unknown
- 2018-10-25 JP JP2020523445A patent/JP7217273B6/ja active Active
- 2018-10-25 HU HUE18800513A patent/HUE062460T2/hu unknown
- 2018-10-25 LT LTEP20197194.2T patent/LT3786160T/lt unknown
- 2018-10-25 MY MYPI2020001894A patent/MY202126A/en unknown
- 2018-10-25 SI SI201830924T patent/SI3700902T1/sl unknown
-
2020
- 2020-04-19 IL IL274039A patent/IL274039B/en unknown
- 2020-04-23 CL CL2020001097A patent/CL2020001097A1/es unknown
- 2020-04-26 SA SA520411843A patent/SA520411843B1/ar unknown
- 2020-04-27 PH PH12020550503A patent/PH12020550503A1/en unknown
- 2020-05-04 ZA ZA2020/02372A patent/ZA202002372B/en unknown
- 2020-09-22 IL IL277493A patent/IL277493B/en unknown
- 2020-10-02 CL CL2020002562A patent/CL2020002562A1/es unknown
- 2020-10-06 AU AU2020250185A patent/AU2020250185B2/en active Active
- 2020-10-08 JP JP2020170563A patent/JP6979502B2/ja active Active
- 2020-12-08 US US17/115,667 patent/US20210163449A1/en not_active Abandoned
-
2021
- 2021-05-28 US US17/334,097 patent/USRE49699E1/en active Active
-
2022
- 2022-08-18 CY CY20221100560T patent/CY1125488T1/el unknown
-
2023
- 2023-06-07 CY CY20231100270T patent/CY1126109T1/el unknown